FormWeb • bortezomib

Recommendation for Dose Modification for Bortezomib-Related Neuropathic Pain and/or Peripheral Sensory Neuropathy Approved for LSC / OHSU / TVC use ONLY
	If patient develops Grade 1 painful or Grade 2 PN (interfering with function but not with activities of daily living)	If Grade 1 painful or Grade 2 PN persists despite first dose reduction	If patient develops Grade 2 painful or Grade 3 PN (interfering with activities of daily living)	If patient develops Grade 4 PN (sensory neuropathy which is disabling or motor neuropathy that is life-threatening or leads to paralysis)
Starting Dose of bortezomib	1st Dose Reduction	2nd Dose Reduction	Withold bortezomib until toxicity resolves (Grade 1 or less)	Discontinue bortezomib
1.3 mg/m2 on days 1, 4, 8, and 11	1 mg/m2 on days 1, 4, 8, and 11	1 mg/m2 once per week	Resume dosing at 0.7 mg/m2 once per week	Discontinue bortezomib permanently
1.3 mg/m2 on days 1, 8, 15, and 22	1 mg/m2 on days 1, 8, 15, and 22	0.7 mg/m2 on days 1, 8, 15, and 22
1.5 mg/m2 on days 1, 8, 15 and 22	1.3 mg/m2 on days 1, 8, 15 and 22	1 mg/m2 on days 1, 8, 15 and 22
Grading based on CTEP Version 4.0 of the NCI Common Terminology Criteria for Adverse Events (CTCAE)

Origination Date: 18Nov2015; Approved by OHSU HOPE Committee 04Dec2015; OHSU/TVC/LSC use ONLY

Last updated: Mar. 28, 2022

High Alert: CAUTION: See High-Alert Medication Policy
Antineoplastic HD PPE and Disposal
Antineoplastic HD Hazardous Drug Safe Handling Policy
RCRA: Disposal
RCRA: Management of Pharmaceutical Waste Policy

This site is intended for the staff of Legacy Health.
While others may view accessible pages, Legacy Health makes no warranty, express or implied,
as to the use of this information outside of Legacy Health.